Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular Immunotherapy
Abstract
Cancer immunotherapy comprises different therapeutic strategies that exploit the use of distinct components of the immune system, with the common goal of specifically targeting and eradicating neoplastic cells. These varied approaches include the use of specific monoclonal antibodies, checkpoint inhibitors, cytokines, therapeutic cancer vaccines and cellular anticancer strategies such as activated dendritic cell (DC) vaccines, tumor-infiltrating lymphocytes (TILs) and, more recently, genetically engineered T cells. Each one of these approaches has demonstrated promise, but their generalized success has been hindered by the paucity of specific tumor targets resulting in suboptimal tumor responses and unpredictable toxicities. This review will concentrate on recent advances on the use of engineered T cells for adoptive cellular immunotherapy (ACI) in cancer.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CAR-T-cell therapy can mitigate the off-target toxicities associated with low antigen affinity in traditional TCRs.
“Additionally, CAR-T-cell therapy can mitigate the off-target toxicities associated with low antigen affinity in traditional TCRs [64].”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [64]
Cites
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974 · see citing works
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1× · see citing works
“Proviral DNA integration loci near transcriptional start sites may lead to proto-oncogene activation and have resulted in oncogenesis in viral-mediated gene modification of hematopoetic stem cells [146, 147].”
BackgroundAAV hybrid serotypes: improved vectors for gene delivery
Choi, V., McCarty, D., & Samulski, R. (2005) · Current Gene Therapy · doi:10.2174/1566523054064968 · Cited by 191 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691 · see citing works
Evmorfopoulos, K., Marsitopoulos, K., Karachalios, R., Karathanasis, A., Dimitropoulos, K., Tzortzis, V., Zachos, I., & Vlachostergios, P. J. (2024) · Cancers · doi:10.3390/cancers16020428 · Cited by 11 · see citing works
“Additionally, CAR-T-cell therapy can mitigate the off-target toxicities associated with low antigen affinity in traditional TCRs [64].”
BackgroundPantuck, M., Palaskas, N., & Drakaki, A. (2018) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2018.08.001 · Cited by 7 · see citing works
- Authors
- Figueroa, J. A., Reidy, A., Mirandola, L., Trotter, K., Suvorava, N., Figueroa, A., Konala, V., Aulakh, A., Littlefield, L., Grizzi, F., Rahman, R. L., R. Jenkins, M., Musgrove, B., Radhi, S., D'Cunha, N., D'Cunha, L. N., Hermonat, P. L., Cobos, E., & Chiriva-Internati, M.
- Affiliations
- Texas Tech University (US)
- University of Arkansas for Medical Sciences (US)
- Venue
- International Reviews of Immunology
- Publisher
- Informa UK Limited
- Published
- 2015-03-04
- Volume
- 34
- Issue
- 2
- Pages
- 154-187
- ISSN
- 0883-0185 (ISSN-L)
- 1563-5244
- OpenAlex
- W2054616684
- Cited by
- 78
- References
- 3
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 9 · 2023: 7 · 2022: 7 · 2021: 6 · 2020: 13 · 2019: 5 · 2018: 9 · 2017: 10 · 2016: 4 · 2015: 3
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Reviews of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- chimeric antigen receptor, chimeric antigen receptor T cells, adoptive cellular immunotherapy, cancer immunotherapy, genetically modified T cells, tumor-specific antigens, T cell engineering, cancer vaccines, tumor-infiltrating lymphocytes, dendritic cell vaccine
- MeSH terms
- Animals, Genetic Engineering, Humans, Neoplasms, Receptors, Antigen, T-Cell, Recombinant Fusion Proteins, T-Lymphocytes, Immunotherapy, Adoptive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
